Physiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF hamster model at the Keystone Symposia on type 2 diabetes therapeutics in Palm Springs, CA, USA May 1-4, 2023.
This unique preclinical model will be presented during the May 2nd poster session (poster #1005) from 7:30pm by Dr. François Briand, Director of Research and Business Development at Physiogenex, and Dr. Rana Assaly, Director of Scientific and Business Development at Cardiomedex.
Unlike mouse and rat, the diabetic NASH HFpEF hamster has a human-like lipoprotein/bile acids profile, shows evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis, and develops alteration in kidney function and severe heart failure with preserved ejection fraction (HFpEF). This preclinical model represents a unique opportunity to evaluate the cardiometabolic benefits of drugs targeting type 2 diabetes and/or its complications.
Reach out to François Briand or Rana Assaly during the Keystone conference to learn how Physiogenex and Cardiomedex animal models and CRO services will drive your preclinical drug development to success.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand or Dr. Assaly and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.
Cardiomedex, a subsidiary company of Physiogenex, is a highly skilled preclinical CRO specialized in the cardiovascular field.
Cardiomedex conducts reliable studies that optimize the preclinical development of drug candidates for the treatment of cardiovascular diseases and cardiometabolic complications. Our large selection of gold standard animal models covers cardiovascular disorders, and we provide our clients with personalized consulting services in line with the pharma industry’s emerging trends.